241 related articles for article (PubMed ID: 27093372)
21. Immunogenicity and protective efficacy of a fusion protein vaccine consisting of antigen Ag85B and HspX against Mycobacterium tuberculosis infection in mice.
Li Q; Yu H; Zhang Y; Wang B; Jiang W; Da Z; Xian Q; Wang Y; Liu X; Zhu B
Scand J Immunol; 2011 Jun; 73(6):568-76. PubMed ID: 21323695
[TBL] [Abstract][Full Text] [Related]
22. Improved immunogenicity of recombinant Mycobacterium bovis bacillus Calmette-Guérin strains expressing fusion protein Ag85A-ESAT-6 of Mycobacterium tuberculosis.
Deng YH; Sun Z; Yang XL; Bao L
Scand J Immunol; 2010 Oct; 72(4):332-8. PubMed ID: 20883318
[TBL] [Abstract][Full Text] [Related]
23. Recombinant Mycobacterium bovis BCG for immunotherapy in nonmuscle invasive bladder cancer.
Begnini KR; Buss JH; Collares T; Seixas FK
Appl Microbiol Biotechnol; 2015 May; 99(9):3741-54. PubMed ID: 25794874
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of protective efficacy conferred by a recombinant Mycobacterium bovis BCG expressing a fusion protein of Ag85A-ESAT-6.
Deng YH; He HY; Zhang BS
J Microbiol Immunol Infect; 2014 Feb; 47(1):48-56. PubMed ID: 23357605
[TBL] [Abstract][Full Text] [Related]
25. IL-21 inhibits IL-17A-producing γδ T-cell response after infection with Bacillus Calmette-Guérin via induction of apoptosis.
Huang Y; Matsumura Y; Hatano S; Noguchi N; Murakami T; Iwakura Y; Sun X; Ohara N; Yoshikai Y
Innate Immun; 2016 Nov; 22(8):588-597. PubMed ID: 27554052
[TBL] [Abstract][Full Text] [Related]
26. Recombinant BCG coexpressing Ag85B, CFP10, and interleukin-12 induces multifunctional Th1 and memory T cells in mice.
Lin CW; Su IJ; Chang JR; Chen YY; Lu JJ; Dou HY
APMIS; 2012 Jan; 120(1):72-82. PubMed ID: 22151310
[TBL] [Abstract][Full Text] [Related]
27. Enhanced and durable protective immune responses induced by a cocktail of recombinant BCG strains expressing antigens of multistage of Mycobacterium tuberculosis.
Liang J; Teng X; Yuan X; Zhang Y; Shi C; Yue T; Zhou L; Li J; Fan X
Mol Immunol; 2015 Aug; 66(2):392-401. PubMed ID: 25974877
[TBL] [Abstract][Full Text] [Related]
28. A novel DNA vaccine for protective immunity against virulent Mycobacterium bovis in mice.
Liu S; Gong Q; Wang C; Liu H; Wang Y; Guo S; Wang W; Liu J; Shao M; Chi L; Zhao K; Wang Z; Shi Y; Huang Y; Guli A; Zhang C; Kong X
Immunol Lett; 2008 May; 117(2):136-45. PubMed ID: 18339431
[TBL] [Abstract][Full Text] [Related]
29. Anti-interleukin-10R1 monoclonal antibody enhances bacillus Calmette-Guérin induced T-helper type 1 immune responses and antitumor immunity in a mouse orthotopic model of bladder cancer.
Bockholt NA; Knudson MJ; Henning JR; Maymí JL; Weady P; Smith GJ; Eisenbraun MD; Fraser JD; O'Donnell MA; Luo Y
J Urol; 2012 Jun; 187(6):2228-35. PubMed ID: 22503050
[TBL] [Abstract][Full Text] [Related]
30. Treatment of bladder carcinomas using recombinant BCG DNA vaccines and electroporative gene immunotherapy.
Lee CF; Chang SY; Hsieh DS; Yu DS
Cancer Gene Ther; 2004 Mar; 11(3):194-207. PubMed ID: 14973549
[TBL] [Abstract][Full Text] [Related]
31. A novel recombinant BCG-expressing pro-apoptotic protein BAX enhances Th1 protective immune responses in mice.
Li G; Liu G; Song N; Kong C; Huang Q; Su H; Bi A; Luo L; Zhu L; Xu Y; Wang H
Mol Immunol; 2015 Aug; 66(2):346-56. PubMed ID: 25942359
[TBL] [Abstract][Full Text] [Related]
32. Immunomodulatory effects of recombinant BCG expressing pertussis toxin on TNF-alpha and IL-10 in a bladder cancer model.
Chade DC; Borra RC; Nascimento IP; Villanova FE; Leite LC; Andrade E; Srougi M; Ramos KL; Andrade PM
J Exp Clin Cancer Res; 2008 Nov; 27(1):78. PubMed ID: 19040745
[TBL] [Abstract][Full Text] [Related]
33. Importance of urinary interleukin-18 in intravesical immunotherapy with bacillus calmette-guérin for superficial bladder tumors.
Eto M; Koga H; Noma H; Yamaguchi A; Yoshikai Y; Naito S
Urol Int; 2005; 75(2):114-8. PubMed ID: 16123563
[TBL] [Abstract][Full Text] [Related]
34. Construction of recombinant human IFNα-2b BCG and its antitumor effects on bladder cancer cells in vitro.
Sun E; Nian X; Liu C; Fan X; Han R
Genet Mol Res; 2015 Apr; 14(2):3436-49. PubMed ID: 25966110
[TBL] [Abstract][Full Text] [Related]
35. Additive antitumor effect of arsenic trioxide combined with intravesical bacillus Calmette-Guerin immunotherapy against bladder cancer through blockade of the IER3/Nrf2 pathway.
Mao MH; Huang HB; Zhang XL; Li K; Liu YL; Wang P
Biomed Pharmacother; 2018 Nov; 107():1093-1103. PubMed ID: 30257321
[TBL] [Abstract][Full Text] [Related]
36. Immunogenicity and protective efficacy of a tuberculosis DNA vaccine expressing a fusion protein of Ag85B-Esat6-HspX in mice.
Yuan W; Dong N; Zhang L; Liu J; Lin S; Xiang Z; Qiao H; Tong W; Qin C
Vaccine; 2012 Mar; 30(14):2490-7. PubMed ID: 21704108
[TBL] [Abstract][Full Text] [Related]
37. Immunotherapy for bladder cancer using recombinant bacillus Calmette-Guerin DNA vaccines and interleukin-12 DNA vaccine.
Lee CF; Chang SY; Hsieh DS; Yu DS
J Urol; 2004 Mar; 171(3):1343-7. PubMed ID: 14767345
[TBL] [Abstract][Full Text] [Related]
38.
Rodriguez D; Goulart C; Pagliarone AC; Silva EP; Cunegundes PS; Nascimento IP; Borra RC; Dias WO; Tagliabue A; Boraschi D; Leite LCC
Front Immunol; 2019; 10():1460. PubMed ID: 31297119
[TBL] [Abstract][Full Text] [Related]
39. A novel immunotherapy for superficial bladder cancer by the immobilization of streptavidin-tagged bioactive IL-2 on the biotinylated mucosal surface of the bladder wall.
Huang X; Yu HS; Chen Z; Li JL; Hu ZM; Gao JM
Chin J Cancer; 2010 Jun; 29(6):611-6. PubMed ID: 20507734
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of immunogenicity and protective efficacy against Mycobacterium tuberculosis infection elicited by recombinant Mycobacterium bovis BCG expressing human Interleukin-12p70 and Early Secretory Antigen Target-6 fusion protein.
Deng Y; Bao L; Yang X
Microbiol Immunol; 2011 Nov; 55(11):798-808. PubMed ID: 21831202
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
